Cost-Effectiveness Thresholds in Europe: Why There Is No Single Answer

Companies often ask what cost per QALY will be accepted in Europe. The honest answer is that there is no single figure, and the better question is how each system uses economic evidence.

Different systems, different roles

Health technology assessment is organised nationally, and so is the use of economic evaluation. Some bodies publish explicit ranges for the cost per quality-adjusted life year. Others use economic evidence as one input among several, or rely on different methods to judge value. The EU HTA Regulation harmonises the joint clinical assessment, but economic evaluation, pricing and reimbursement remain national decisions.

What a QALY-based analysis involves

A standard cost-utility analysis compares the costs and health outcomes of a new treatment against current care. Its credibility depends on the following elements.

  • Comparator: it must reflect what the local health system actually uses.
  • Time horizon and extrapolation: long-term claims from short-term trials need transparent justification.
  • Utility values: the source and method must be acceptable to the local assessor.
  • Uncertainty: sensitivity analyses should show which assumptions matter most.

The Greek context

In Greece, published descriptions list cost-effectiveness among the criteria weighed in assessment, while the Negotiation Committee handles economic evaluation and price discussions alongside budget impact. That means the economic case is tied to the commercial conversation rather than being a standalone pass-or-fail test. A well-built model remains valuable because it supports the case for a price and for any proposed agreement.

Practical advice

Build a core model that can be adapted, not a different model for each country. Keep inputs and structure transparent so a local reviewer can replace assumptions with national data. Present results with their uncertainty, and explain clearly what drives them. Remember that a favourable ratio does not remove affordability concerns, which budget impact analysis addresses separately.

Avoiding common mistakes

Several weaknesses appear often in economic submissions. Models built around a comparator that is not used locally are discounted. Long-term extrapolation with no supporting data attracts scepticism. Utility values drawn from sources that do not reflect the target population invite challenge. And results presented without scenario analysis leave reviewers unable to judge robustness.

Better practice is to document each key assumption, explain its source, and show what happens when it changes. A model that is transparent about its drivers lets the discussion focus on the real uncertainties, and it gives the company a firmer basis for negotiating price and conditions.

How PQRA helps

PQRA can help review the structure of your economic evidence and plan its adaptation for Greece and other European markets, in coordination with regulatory and pricing strategy.

To discuss the economic evidence for your product, Contact PQRA.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *